Mandate

Lendify has secured new financing of up to SEK 1,500,000,000 from, amongst others, Insight Investment

June 11, 2019 Banking and Finance

Together with, amongst others, the management of the company, the arranger and legal advisors to the arranger, Vinge has acted for Lendify in the structuring, documenting and execution of the transaction where one of the world’s largest and most well established asset managers, Insight Investment, acted as main investor.

The transaction is one of the first in Sweden to be executed and reported under the new EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and to be subject to the new reporting requirements thereunder.

Lendify has, with Vinge’s assistance, secured financing of approximately SEK 2,800,000,000 during the spring of 2019, primarily by completion of the above mentioned transaction, by completion of the transaction with a large Swedish institution previously announced in February and by establishing a credit facility with Nordea.

Vinge’s team mainly consisted of partner Albert Wållgren, associates Lionardo Ojeda and Axel Jansson (Banking and Finance) and partner Emma Stuart Beck and associate Caroline Krassén (Financial Services).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025